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Hemangiomas are benign mesenchymal liver tumors with a
prevalence of 3e20% in autopsy series [1]. Hemangiomas most
commonly affect women in their fourth and fifth decades of life.
Liver hemangiomas are usually asymptomatic, and liver function
tests are typically within normal limits. Hence, they mostly detec-
ted incidentally. Hemangiomas greater than 5 cm are referred to as
giant hemangiomas, which can be symptomatic and require
treatment [2]. Although surgery is the usual treatment method for
symptomatic giant hemangiomas, surgical resection continues to
be the classical paradigm [3]. Minimally invasive techniques have
recently been introduced as alternatives to surgery. In this pro-
spectively study, we aimed to determine the effects of the mini-
mally invasive embolizationwith bleomycinmixed with lipiodol on
mass size and symptoms of patients with giant liver hemangiomas.
2. Methods
In the present study 17 patients [10 women, 7 men; Age range
35e67 years (mean 46,41 ± 2,6 years)] with giant liver hemangi-
omas who presented to our clinic between August 2014 and
October 2016 were treated with minimally invasive approach using
hemangioma embolization with bleomycin mixed with lipiodol.
Two patients underwent a second session of embolization one* Corresponding author. FCIS Baskent University, Taskent Caddesi No: 77, Bah-
celievler, Ankara, 06490, Turkey.
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ment of hemangiomas in two different lobes of the liver. Tumor
characterization (length, lesion number) was performed with ul-
trasonography, computerized tomography (CT) or magnetic reso-
nance imaging. The diagnosis was confirmed by noninvasive
examination and the typical angiographic characteristics noted
during the Transarterial chemoembolization (TACE) procedure.
Following the placement of a 4F introducer into the right
femoral artery under standard sterile conditions, the celiac root was
selectively cannulized using a 4F shepherd hook catheter, and im-
ages were taken after contrast material injection. The acquired cine
films were used to assess large caliber hypervascular mass lesions
supplied by the hepatic artery branch at the side of a liver hem-
angioma. Following the acquisition of diagnostic images, super-
selective catheterization of the above-described mass lesions was
carried out using a microcatheter and a 0.016-inch guidewire.
Bleomycin and lipiodol mixture was injected through a micro-
catheter for the embolization procedure (Fig. 1). Fifteen milligrams
of bleomycin sulphate [Bleosin-S (in 15 mg vials); Onko/Koçsel,
Turkey] was dissolved in 5 ml saline solution and admixed with
10 ml lipiodol (Laboratoire Guerbet, Fransa) at 1:2 ratio. Lipiodol
and bleomycin (10e20 mg/ml) dosages were determined by tumor
diameter (cm), and a maximum of 30 mg bleomycin and 20 ml
lipiodol were used for tumors greater than 10 cm.
During the follow-up, all patients were considered symptomatic
due to an increase in hemangioma size. Additionally, eleven pa-
tients were considered symptomatic owing to a sense of fullness in
the right upper quadrant; five owing to pain; and one owing to liver
failure. All patients were informed about therapeutic and surgical
treatment methods currently available for giant liver hemangi-
omas. All patients gave written informed consent, and the study
was approved by the local ethics committee of Bas¸kent University.
The main portal vein was patent in all patients. A scintigraphic
examination proved the absence of an arterioportal or arteriove-
nous shunt. All patients had an INR of less than 1.5 and a throm-
bocyte count above 50.000/ml. Complete blood count a liver
function tests were evaluated before and 1 day after the procedure.
All patients were administered analgesics and sedatives prior to thean open access article under the CC BY-NC-ND license (http://creativecommons.org/
nt Universitesi from ClinicalKey.com by Elsevier on May 06, 2019.
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Fig. 1. Selective angiographic transarterial chemoembolization procedure.
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zolin 1 g I.V) prophylactic antibiotic immediately before the pro-
cedure. Analgesics and antiemetics were repeated as needed after
the procedure. All patients were hospitalized for the embolization
procedure. The range of hospital stay was 24e72 h (24 h in 15
patients; 48 h in 1 patient; and 72 h in 1 patient) and the mean
duration of hospital stay was 28 h.
Bleomycin-lipiodol mixture was prepared as below:
Tumor size after embolization with bleomycin was assessed by
computerized tomography at 1, 6, and 12 months. Hemangioma
volume was calculated by multiplying its height, length, and width.
The range of the duration of post-procedural clinical and radio-
logical follow-up was 12e16 months (mean 14.47 ± 2.21 months).
Treatment response was analyzed using SPSS 15.0 (Chicago,
USA) software package. Wilcoxon test was used to test whether the
distributions of two variables were equal, and the Firedman ANOVA
test to compare the median values. Patients age and tumor size was
expressed as mean ± SD; statistical significance was set at p ¼ 0.05.
3. Results
Seven patients had hemangiomas in the right lobe; 2 in the left
lobe, and 8 in both lobes. The diameter of the largest hemangioma
was 28 cm. The volumes of the hemagiomas ranged between 480
and 9925.1 cm3. Eleven (64.8%) patients were diagnosed with ul-
trasonography (USG), and 6 (35.2%) with CT. A total of 22 emboli-
zation sessions using the bleomycin lipiodol mixture were carried
out for 19 hemangiomas of 17 patients. Radiological examination
revealed a marked reduction in the mean hemangiomasize after
embolization with bleomycin. The largest diameter of hemangi-
omas was reduced from 14.72 ± 12.8 cm3 to 7.63 ± 4.76 cm3. The
mean volume of the hemangiomas was 3716.276 cm3
(480.0e9925.1 cm3) prior to the procedure and 746.012 cm3
(38.7e3856 cm3) at 12 months. Thepre-procedural hemagioma
volumes and diameters were significantly different from one-, six-,
and twelve-month values. The mean tumor volume was
746 ± 405.7 cm3 at 14 months of follow-up.
The mean volume of giant liver hemangiomas was reduced by
54.9% at 1 month after the procedure compared to the pre-
procedural volume (p < 0.001). The volume reduction reached
79.6% at 6 and 12 months. The non-intervened hemangiomas, on
the other hand, were reduced in volume by 50.8% at 1 month and
75.7% at 12 months, which was radiologically significant but not
statistically significant owing to the low number of hemangiomas
(Figs. 2 and 3).
All patients enjoyed a symptomatic improvement following
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eliminated by 2 months. The regression of the sense of fullness was
proportional to a reduction in the size of the mass. No symptom
recurrence was observed during the follow-up period.
Seven patients developed post-procedural postembolization
syndrome characterized by pain, fever, loss of appetite or nausea.
The most prominent symptom of this syndrome was abdominal
pain. Pain in the right upper quadrant started immediately
following the procedure in all patients, and subsided by 24 h in 15
patients and 48 h in the remainders. Ten patients developed mild
nausea and loss of appetite accompanied by pain. Four patients
developed a subfebrile body temperature not exceeding 37.5 C,
which also subsided by 24 h. No statistically significant increase
occurred in liver enzymes (aspartate amino transferase, alanine
amino transferase) at 24 h after the procedure. No clinically
meaningful increase occurred in white blood cell count, either. No
serious procedural complications developed during follow-up
period, such as liver function disorders, liver abscess, or necrosis
of normal liver tissue. No patient developed pulmonary symptoms
after the procedure. A patient developed a drop in the hemoglobin
level that necessitated the infusion of 2 packs of red blood cell
suspension. No pathology was detected by a control ultrasonogra-
phy, and the patient was discharged uneventfully at the end of 72 h
(Table 1).
4. Discussion
Cavernous hemangiomas are the most common type of benign
tumors of the liver [1,5]. Most are small, asymptomatic and detected
incidentally by radiological screening [6]. Giant cavernous hemangi-
omasmay cause symptoms such as pain, abdominal sense of fullness,
and upper abdominal mass. Thrombosis, infarction, intralesional
bleeding, capsulardistention, and compressingof adjacent organs are
the possible causes of pain [7]. In some rare occasions, serious com-
pications such as obstructive jaundice, Kasabach-Merritt syndrome,
gastric outlet obstruction, orintra-abdominal hemorrhage due to
rupturemay occur [8]. Literature data suggest that the risk of rupture
of liver hemangiomas ranges between 1% and 4%. Giant subcapsular
lesions may be considered to confer a greater risk [9]. Although
hemangiomas do not typically grow in size during follow-up, spon-
taneous growth constitutes the main treatment indication. Steroids
and estrogen therapy may also increase their size. No malignant
transformation of hemangiomas has been reported [10]. In accor-
dance with the literature data, our patients suffered from hemangi-
omagrowth, senseof abdominal fullness, andpain. Thediagnosiswas
made by diagnostic USG and tomographic examination. Spontaneous
growth occurred in hemangiomas during pre-procedural follow-up.niversitesi from ClinicalKey.com by Elsevier on May 06, 2019.
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Fig. 2. One-year follow-up of a giant liver hemangioma; A: computerized tomographic (CT) examination of the giant liver hemangioma before bleomycin embolization, B: CT
examination 1 month after bleomycin embolization, C: CT examination 6 months after bleomycin embolization, D: CT examination 12 months after bleomycin embolization.
Fig. 3. A; Comparison of giant hemangioma size at 1, 6, and 12 months after embolization with bleomycin with pre-procedural size, B; Comparison of the size of the second non-
intervened hemangiomas at 1, 6, and 12 months with pre-procedural size.
Table 1
Demographic properties of patients with giant liver hemangiomas.
Patients Ages Sex Complaint Diagnosis Localization Number Volume-1 Volume-2 Volume-3 Complication
1 42 F pain/enlargement CT bilateral multiple 89.6 190.4 64 no
2 42 M pain/enlargement USG bilateral multiple 880.4 797.94 39.9 no
3 59 F Feeling of fullness/growth USG bilateral 2 4576 405 low hemoglobin
4 47 F Feeling of fullness/growth USG bilateral multiple 510.3 fever and vomiting
5 48 M Feeling of fullness/growth USG bilateral 3 946 470.7 no
6 54 F Feeling of fullness/growth CT Right lob 1 600 no
7 39 F Feeling of fullness/growth USG Right lob 1 101 no
8 48 F pain/enlargement USG Bilateral multiple 600 no
9 67 F pain/enlargement CT Right lob 1 1340.9 no
10 49 F pain/enlargement USG Right lob 2 3021 400 no
11 47 F Feeling of fullness/growth CT Right lob 1 770 no
12 35 M Feeling of fullness/growth USG Right lob 1 658 no
13 52 M Feeling of fullness/growth USG Left lob multiple 831.6 no
14 40 M growth/Liver failure CT bilateral multiple 3705 no
15 37 M Feeling of fullness/growth USG bilateral multiple 144 229 108 no
16 45 F Feeling of fullness/growth USG Left lob multiple 1510.2 no
17 38 M Feeling of fullness/growth CT Right lob 1 810 no
F; Female, M; Male, USG; ultrasonography, CT; computerized tomography.
M. Kirnap et al. / International Journal of Surgery Open 12 (2018) 12e1614No complication developed in any of our patients during a mean
follow-up period of 14 months.
The etiology of hemangiomas is not clear. Structurally, heman-
giomas are composed of venous pools lined by vascular endothelial
cells separated by fibrous tissue septae. Blood circulation is slow,Downloaded for Anonymous User (n/a) at ULAKBIM Academic  Baske
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treatment options for symptomatic liver hemangiomas include
steroids, radiotherapy, surgical resection, hepatic artery ligation,
and transarterial embolization (TACE) [12]. Asymptomatic liver
hemangiomas, on the other hand, have no definitive indications fornt Universitesi from ClinicalKey.com by Elsevier on May 06, 2019.
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growth [3].
The decision for performing surgery for liver hemangiomas
should be carefully weighed against the complication risk. A
number of series have reported serious blood loss (10e27%) and
death at a rate of 0e2% after the enucleation or resection of hepatic
hemangiomas [11]. Surgical resection is controversial even in the
case of symptomatic hemangiomas owing to the risk of severe
complications. The definitive indications for surgery include
intraperitoneal bleeding, intratumoral bleeding, and consumption
coagulopathy (Kasabach-Merritt syndrome) and spontaneous or
traumatic rupture. Nevertheless, spontaneous rupture is an
extremely rare complication even with giant hemangiomas [9]. As
reported previously, other definitive indications for surgery, such as
Kasabach-Merritt syndrome, can also be corrected by embolization
[13]. Surgery should be reserved for patients with giant liver
hemangiomas in whom the non-surgical treatment fails. Although
our patients had no contraindication for surgery, they were suc-
cessfully treated in a minimally invasive manner, i. e by emboliza-
tion with bleomycin. By this way, they were protected against the
complications of surgery.
Recent studies have emphasized the importance of the role of
TACE to treat symptomatic hemangiomas as an effective treatment
method that is less invasive than surgery [5]. To date, several
different embolic agents like gelating sponge, steel coils, polyvinyl
alcohol (PVA), ethanol, sodium morphate, and isobutyl cyano-
acrylate have been used to treat hemangiomas [14]. However,
liquid embolic agents like PVA and sodium morphate or ethanol
may lead to serious complications such as severe pain, and may
cause reflux embolization. Gelatin sponge alone does not destroy
blood sinuses [4]. Bleomycin is an antimycotic and antimicrobial
agent used against squamous cell carcinomas, testis cancers, and
malignant lymphomas. Its antineoplastic activity stems from its
inhibition of DNA biosynthesis [15]. Oikawa et al. [16] first reported
the antiangiogenic action of bleomycin in 1990. Bleomycin exerts a
local sclerosing action on endothelial cells. Bleomycin, alone or
mixedwith iodized oil (lipiodol), can be used as a sclerosing agent to
treat vascular anomalies [17]. The mechanism of the antiangiogenic
effects of bleomycin is unknown. Animal studies have suggested
that injury starts in capillaries in the form of endothelial cell pyk-
nosis, thrombocyte aggregation, and intraluminal thrombus for-
mation, ultimately inducing fibroblast proliferation and collagen
deposition [18]. Pulmonary fibrosis is the most severe pulmonary
complication of bleomycin. Bleomycin-induced pulmonary fibrosis
has not been reported for doses used to treat hemangiomas, how-
ever [18]. Pulmoner fibrosis is seen in 30% of patients in whom the
cumulative bleomycin dose exceeds 450 mg [15]. In this study, the
maximum bleomycin dose was substantially lower than the toxic
dose; we therefore encountered no case of pulmonary fibrosis.
Lipiodol (iodized oil) is used as an embolic agent and anticancer
drug carrier. It is selectively accumulated in vascular sinuses [19].
Lipiodol not only invades small arteries supplying a tumor, but it
also carries bleomycin to it. Arteriovenous shunts inside hepatic
cavernous hemangiomas are extremely rare [20]. Studies on animals
and humans have demonstrated that lipiodol remains in small ar-
teries and sinusoids of a tumor [19]. The mechanism of effect of
bleomycin mixed with lipiodol is thought to be the destruction of
endothelial cells and formation of microthrombin in sinuses, ulti-
mately resulting in the atrophy and fibrosis [4]. Additionally, bleo-
mycinmixedwith lipiodol does not harm normal blood vessels. This
study demonstrated a variable reduction of hemangioma size at
3e12 months after embolization. The difference between heman-
giomas size post-and pre-embolization was statistically significant.
We suggest that bleomycin and lipiodol have a superior effect on
embolization than solid embolic agents. Bleomycin mixed withDownloaded for Anonymous User (n/a) at ULAKBIM Academic  Baskent U
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sclerozing agent that induces fibrosis. The fibrotic effect of bleo-
mycin mixed with lipiodol as well as the reduction in hemangioma
size and blood supply of hemangiomas were radiologically showed
during 12-month follow-up of the patients.
Thanks to its relatively modest embolization effect, bleomycin
mixed with lipiodol is safer than liquid embolic agents like sodium
morphate and ethanol. The most common side effects of emboli-
zation are pain, fever, leucocytosis, and nausea. The postemboliza-
tion syndrome lasts several days and serious complications are rare
[21]. Our patients suffered mild-moderate postembolization syn-
drome, and none of them developed liver failure. Even a patient
with preexisting liver failure tolerated the procedure well. This may
be due to lipiodol being not taken by a normal hepatic tissue but
rapidly cleared through hemangiomatous sinusoids.
5. Conclusions
This prospectively study showed that the embolization of giant
liver hemangiomas with bleomycin and lipiodol mixture elimi-
nated symptoms and reduced lesion size. Embolization with bleo-
mycin mixed with lipiodol is an effective alternative to surgery in
these patients.
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